References
- 1. Lichtman LA, Liesveld JL. CML and related disorders, in Williams Hematology, McGraw Hill 8th edition, 1085-1124.
- 2. Petrov L, Cucuianu A, Bojan A, Urian L. Leucemia granulocitara cronica. In “Hematologie Clinica”. Casa Cartii de Stiinta, Cluj-Napoca, 2009: 45-63
- 3. Apperley JF. Mechanism of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol, 2007, 8:1018-102910.1016/S1470-2045(07)70342-X
- 4. Quintas-Guardama A, Kantarjian H, Cortes J. Mechanism of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control, 2009, 16: 122-131.10.1177/10732748090160020419337198
- 5. Bixby D, Talpaz M. Mechanism of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology 2009, 1: 461-47610.1182/asheducation-2009.1.46120008232
- 6. Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D et al. Mutation status and clinical outcome of 89 imatinib mesylate- resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML. Leukemia 2006, 20: 1061-106610.1038/sj.leu.240423616642048
- 7. Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M et al. Clinical outcome of 27 imatinib mesylate resistant chronic myelogenous leukemia patients harboring T315I BCR-ABL mutation. The Hematology Journal 2007, 92: 1238-124110.3324/haematol.1136917768119
- 8. Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 2009, 114: 5271-5278.10.1182/blood-2009-04-219410491693919843886
- 9. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Muller MC et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol, 2009, 27: 4204-421010.1200/JCO.2009.21.8230497923019652056
- 10. Muller Mc, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R et al. Dasatinib treatment of chronic phase chronic myeloid leukemia, analysis of responses according to preexisting BCR-ABL mutations. Blood, 2009, 114:4944-495310.1182/blood-2009-04-214221491694019779040
- 11. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood, 2007, 110: 2828-3710.1182/blood-2007-04-03894317626839
- 12. Roche-Lestienne C, Soenen-Cornu V, Grardel- Duflos N, Laï JL, Philippe N, Facon T et all. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 2002, 100:1014-101810.1182/blood.V100.3.1014
- 13. Khorashad JS, Thelwell N, Milojkovic D, Marin D, Watson JA, Goldman JM, Apperley JF et al. A new rapid and sensitive assay for detecting the chronic myeloid leukemia T315I BCR-ABL kinase domain mutation in chronic myeloid leukemia. J Clin Pathol. 2008, 61, 863-86510.1136/jcp.2008.05680418587017
- 14. Y M Dennis Lo. The amplification refractory mutation system. Methods in Molecular Medicine, 1998, 16: 61-69
- 15. Dima D, Trifa AP, Cucuianu A, Popp RA, Patiu M, Petrov L. Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR. Rev Rom de Med de Lab, 2008, 13:17-20
- 16. Marin D, Ibrahim Amr R, Goldman JM. European treatment and outcome study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol, 2011, 29: 3944-394510.1200/JCO.2011.37.696221900102
- 17. Cortes J, Lipton JH, Rea D, Diqumarti R, Chuah C, Nanda N et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with CML with T315I mutation. Blood, 2012, 120:2573-258010.1182/blood-2012-03-415307491658322896000
- 18. Wei G, Rafiyath S and Liu D. First line treatment of chronic myeloid leukemia: dasatinib, nilotinib or imatinib. J Hematol Oncol, 2010, 3: 47-5210.1186/1756-8722-3-47300036921108851
- 19. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory Philadelphia chromosome- positive leukemias. N Eng J Med, 2012, 367:2075-8810.1056/NEJMoa1205127377738323190221
- 20. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 2011, 118:1208-1215 10.1182/blood-2010-12-32640521562040